[A Case of Radical Nephrectomy that Achieved Complete Remission after Combination Therapy with Pembrolizumab and Lenvatinib for Metastatic Renal Cell Carcinoma].
{"title":"[A Case of Radical Nephrectomy that Achieved Complete Remission after Combination Therapy with Pembrolizumab and Lenvatinib for Metastatic Renal Cell Carcinoma].","authors":"Hitoshi Yokozeki, Takaaki Takuma, Kazuki Kokura, Shoko Uketa, Tomohiro Fukui, Yuichi Uemura, Jun Watanabe","doi":"10.14989/ActaUrolJap_71_3_81","DOIUrl":null,"url":null,"abstract":"<p><p>An 81-year-old woman to our hospital complaining of backpain and was diagnosed with a left renal tumor with lung and iliac metastasis. A renal tumor biopsy confirmed clear cell renal cell carcinoma. The patient began combination therapy with pembrolizumab and lenvatinib but experienced fatigue and edema after 1 month. Suspecting cardiac dysfunction induced by Lenvatinib, Lenvatinib was discontinued and treatment with pembrolizumab alone was continued. Three months after treatment initiation, the lung and iliac metastases had resolved, allowing for laparoscopic nephrectomy. Five months post-surgery, no new metastases were detected.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"71 3","pages":"81-86"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_71_3_81","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
An 81-year-old woman to our hospital complaining of backpain and was diagnosed with a left renal tumor with lung and iliac metastasis. A renal tumor biopsy confirmed clear cell renal cell carcinoma. The patient began combination therapy with pembrolizumab and lenvatinib but experienced fatigue and edema after 1 month. Suspecting cardiac dysfunction induced by Lenvatinib, Lenvatinib was discontinued and treatment with pembrolizumab alone was continued. Three months after treatment initiation, the lung and iliac metastases had resolved, allowing for laparoscopic nephrectomy. Five months post-surgery, no new metastases were detected.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
